Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Charles River Laboratories

Related CRL
4 Medical Stocks That Could Be Big Winners Next Week
A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Yellen Speech
Charles River Labs Re-Enters Buy Zone; Gets Stock Rating Upgrade (Investor's Business Daily)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Charles River Laboratories (NYSE: CRL), and raised its price target from $35.00 to $44.00.

Jefferies noted, “3Q results were better than expected, making the narrowed 2012 guidance more conservative. Getting $3 in 2013 EPS requires PCS to continue to outgrow the industry with improving margin. Incremental margin was attractive YoY, but negative sequentially. CRL needs RMS to perform better than in 3Q and share the load with PCS, not hand it off. The AZN deal should help. We raise our PT and 2013 estimates.”

Charles River Laboratories closed on Tuesday at $39.40.

Latest Ratings for CRL

Jan 2017Evercore ISI GroupUpgradesHoldBuy
Dec 2016Goldman SachsUpgradesSellNeutral
Nov 2016BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (CRL)

View Comments and Join the Discussion!